Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study

Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study

Abstract Background Advanced pancreatic ductal adenocarcinoma (aPDAC) patients have a lifetime all type thromboembolic event (ATTE) rate of 25–35%. Efficacy and safety of increased dose primary thromboprophylaxis (IDPTP) with low molecular heparin (LMWH) given for 3 months has been shown in two pros...

Full description

Bibliographic Details
Main Authors: Anthony Maraveyas, Farzana Haque, Iqtedar Ahmed Muazzam, Waqas Ilyas, George Bozas
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Thrombosis Journal
Subjects:
Pancreatic cancer
Thromboprophylaxis
Dalteparin
Ambulatory
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12959-020-00222-1

Internet

http://link.springer.com/article/10.1186/s12959-020-00222-1

Similar Items